查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566771

Capecitabine市场：按适应症、药物类型和最终用户分类：2024-2033 年全球机会分析和产业预测

Capecitabine Market By Indication (Colorectal Cancer, Breast Cancer, Others) , By Drug Type (Branded, Generic) By End User (Hospitals, Homecare, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球Capecitabine市场价值为4亿美元，预计2024年至2033年复合年增长率为5%，到2033年将达7亿美元。

Capecitabine是一种口服化疗药物，用于治疗多种癌症，包括乳癌、结肠癌和直肠癌。Capecitabine属于一组称为抗代谢药物的药物，其作用是抑制癌细胞的生长和扩散。Capecitabine是前驱药物，在体内转化为其活性形式 5-Fluorouracil(5-FU)。一旦转化，5-FU 就会抑制癌细胞中 DNA 和 RNA 的合成，导致癌细胞死亡。与静脉注射的传统化疗不同，Capecitabine滨是口服的，通常是锭剂形式。这使得患者更加方便，并且通常可以在门诊进行治疗。

Capecitabine市场的成长是由癌症盛行率上升所推动的。随着全球癌症患者数量的不断增加，对有效治疗方案的需求也迅速增加。此外，老年人口的增加已成为Capecitabine市场的关键驱动因素。随着年龄的增长，由于基因突变的累积、免疫系统减弱以及一生中长期接触致癌物质等因素，我们变得更容易罹患癌症。人口老化的转变导致老年人癌症诊断盛行率增加，从而对Capecitabine等有效癌症治疗方法的需求增加。

然而，与Capecitabine相关的副作用，如贫血、胸部不适、呕吐和凝血障碍，正在阻碍市场成长。同时，产品创新、推出和市场多元化为市场参与企业提供了有利的机会。例如，2022年12月，Shilpa Medicare Ltd.宣布推出Capecitabine1,000MG分散片，采用90秒内快速分散的新技术。该产品得到了必要的科学认证和比较生物等效性研究的支持，并得到了印度国家监管局（NRA）的批准，该机构负责确保印度医疗产品的安全性、有效性和质量，并获得药品标准控制组织的核准。该产品用于治疗大肠直肠癌和转移性乳癌。

分部概览

全球Capecitabine市场按适应症、药物类型、最终用户和地区细分。依适应症分为大肠直肠癌、乳癌等。依药品种类，药品分为原厂药和学名药。依最终用户划分，可分为医院、居家医疗、专科中心等。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

有迹象表明，到 2023 年，乳癌细分市场将成为市场的最大股东。

按药物类型划分，品牌细分市场在 2023 年占据最高市场占有率。

按最终用户划分，2023 年医院领域占最大份额。

按地区划分，2023 年北美主导Capecitabine市场。

竞争场景

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章Capecitabine滨市场：依适应症分类

  • 市场概况
  • 大肠直肠癌
  • 乳癌
  • 其他的

第五章Capecitabine滨市场：依药物类型

  • 市场概况
  • 品牌
  • 非专利的

第六章Capecitabine市场：依最终用户分类

  • 市场概况
  • 医院
  • 居家医疗
  • 专科诊所
  • 其他的

第七章Capecitabine滨市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国Capecitabine滨市场
    • 加拿大Capecitabine市场
    • 墨西哥Capecitabine市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国Capecitabine市场
    • 法国Capecitabine市场
    • 英国Capecitabine市场
    • 义大利Capecitabine市场
    • 西班牙Capecitabine市场
    • 其他欧洲Capecitabine市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本Capecitabine市场
    • 中国Capecitabine市场
    • 澳洲Capecitabine滨市场
    • 印度Capecitabine市场
    • 韩国Capecitabine市场
    • 其他亚太Capecitabine滨市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西卡培Capecitabine市场
    • 沙乌Capecitabine市场
    • 南非Capecitabine市场
    • 其他拉丁美洲/中东/非洲Capecitabine市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Novartis AG
  • Bayer AG
  • Eli Lilly And Company.
  • Merck And Co., Inc.
简介目录
Product Code: A03017

The global capecitabine market was valued at $0.4 billion in 2023, and is projected to reach $0.7 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Capecitabine is an oral chemotherapy medication used in the treatment of various cancers, including breast, colon, and rectal cancers. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and spread of cancer cells. Capecitabine is a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), in the body. Once converted, 5-FU inhibits the synthesis of DNA and RNA in cancer cells, leading to their death. Traditional chemotherapy drugs administered intravenously, whereas capecitabine is taken orally, usually in the form of tablets. This offers convenience to patients and allows for outpatient treatment in many cases.

The growth of the capecitabine market is driven by rise in the prevalence of cancer. With the growing number of cancer patients globally, there is surge in demand for the effective treatment option. Moreover, rise in geriatric population has emerged as a significant driver of the capecitabine market. As individuals age, they become more susceptible to developing cancer due to factors such as accumulated genetic mutations, weakened immune systems, and prolonged exposure to carcinogens over their lifetime. This demographic shift toward an aging population has led to a higher prevalence of cancer diagnoses among older adults, creating a greater demand for effective cancer treatments such as capecitabine.

However, adverse effects related to capecitabine, such as anemia, chest discomfort, vomiting, and blood clotting disorders, hamper the growth of the market. On the other hand, product innovation, launches, and diversification present lucrative opportunities for the market players. For instance, in December 2022, Shilpa Medicare Ltd. announced the launch of the Capecitabine 1000 MG dispersible tablet with novel technology of faster dispersion within 90 seconds. The product is supported by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO) -the National Regulatory Authority (NRA) of India, responsible for ensuring the safety, efficacy, and quality of medical products in the country. The product is used for treatment of colorectal and metastatic breast cancer.

Segmentation Overview

The global capecitabine market is segmented into indication, drug type, end user, and region. By indication, the market is divided into colorectal cancer, breast cancer, and others. Depending on drug type, it is categorized into branded and generic. According to end user, the market is classified into hospitals, homecare, specialty centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By indication, the breast cancer segment was the largest shareholder in the market in 2023.

Depending on drug type, the branded segment held the highest market share in 2023.

According to end user, the hospitals segment accounted for the maximum share of the market in 2023.

Region wise, North America dominated the capecitabine market in 2023.

Competitive Scenario

The major players operating in the capecitabine market include F. Hoffmann-La Roche Ltd., Mylan N.V, Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Novartis AG, Bayer AG, Eli Lilly and Company, and Merck & Co., Inc. Other players in the market include GlaxoSmithKline Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, and Alkem Labs Ltd. These players have adopted several strategies, including product diversification & innovation, mergers & acquisitions, and collaborations to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Indication

  • Colorectal Cancer
  • Breast Cancer
  • Others

By Drug Type

  • Branded
  • Generic

By End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • F. Hoffmann-La Roche Ltd.
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Novartis AG
    • Bayer AG
    • Eli Lilly and Company.
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CAPECITABINE MARKET, BY INDICATION

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Indication
  • 4.2. Colorectal Cancer
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Breast Cancer
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Drug Type
  • 5.2. Branded
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Generic
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: CAPECITABINE MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Homecare
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Specialty Clinics
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CAPECITABINE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Indication
    • 7.2.3. Market Size and Forecast, By Drug Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Capecitabine Market
      • 7.2.6.1. Market Size and Forecast, By Indication
      • 7.2.6.2. Market Size and Forecast, By Drug Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Capecitabine Market
      • 7.2.7.1. Market Size and Forecast, By Indication
      • 7.2.7.2. Market Size and Forecast, By Drug Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Capecitabine Market
      • 7.2.8.1. Market Size and Forecast, By Indication
      • 7.2.8.2. Market Size and Forecast, By Drug Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Indication
    • 7.3.3. Market Size and Forecast, By Drug Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Capecitabine Market
      • 7.3.6.1. Market Size and Forecast, By Indication
      • 7.3.6.2. Market Size and Forecast, By Drug Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Capecitabine Market
      • 7.3.7.1. Market Size and Forecast, By Indication
      • 7.3.7.2. Market Size and Forecast, By Drug Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Capecitabine Market
      • 7.3.8.1. Market Size and Forecast, By Indication
      • 7.3.8.2. Market Size and Forecast, By Drug Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Capecitabine Market
      • 7.3.9.1. Market Size and Forecast, By Indication
      • 7.3.9.2. Market Size and Forecast, By Drug Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Capecitabine Market
      • 7.3.10.1. Market Size and Forecast, By Indication
      • 7.3.10.2. Market Size and Forecast, By Drug Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Capecitabine Market
      • 7.3.11.1. Market Size and Forecast, By Indication
      • 7.3.11.2. Market Size and Forecast, By Drug Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Indication
    • 7.4.3. Market Size and Forecast, By Drug Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Capecitabine Market
      • 7.4.6.1. Market Size and Forecast, By Indication
      • 7.4.6.2. Market Size and Forecast, By Drug Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Capecitabine Market
      • 7.4.7.1. Market Size and Forecast, By Indication
      • 7.4.7.2. Market Size and Forecast, By Drug Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. Australia Capecitabine Market
      • 7.4.8.1. Market Size and Forecast, By Indication
      • 7.4.8.2. Market Size and Forecast, By Drug Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. India Capecitabine Market
      • 7.4.9.1. Market Size and Forecast, By Indication
      • 7.4.9.2. Market Size and Forecast, By Drug Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Capecitabine Market
      • 7.4.10.1. Market Size and Forecast, By Indication
      • 7.4.10.2. Market Size and Forecast, By Drug Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Capecitabine Market
      • 7.4.11.1. Market Size and Forecast, By Indication
      • 7.4.11.2. Market Size and Forecast, By Drug Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Indication
    • 7.5.3. Market Size and Forecast, By Drug Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Capecitabine Market
      • 7.5.6.1. Market Size and Forecast, By Indication
      • 7.5.6.2. Market Size and Forecast, By Drug Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Capecitabine Market
      • 7.5.7.1. Market Size and Forecast, By Indication
      • 7.5.7.2. Market Size and Forecast, By Drug Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Capecitabine Market
      • 7.5.8.1. Market Size and Forecast, By Indication
      • 7.5.8.2. Market Size and Forecast, By Drug Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Capecitabine Market
      • 7.5.9.1. Market Size and Forecast, By Indication
      • 7.5.9.2. Market Size and Forecast, By Drug Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. F. Hoffmann-La Roche Ltd.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Mylan N.V.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Teva Pharmaceutical Industries Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Sanofi
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Pfizer Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Dr. Reddy's Laboratories Ltd.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Bayer AG
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Eli Lilly And Company.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Merck And Co., Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments